AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00633984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Description: The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
Study NCT00633984 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Description: The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
Study NCT00633984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
Study NCT00633984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
Study NCT04532112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biocontainment Device For Aerosol Generating Procedures (Biobox)
Description: The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
Study NCT04532112 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control for aerosol generating procedures
Description: There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
Study NCT01459406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 500 ml water drink containing 40g glucose
Study NCT01459406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 500 ml water drink containing 40g fructose
Study NCT01459406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan
Description: 500 ml water drink containing 40g fructan
Study NCT01459406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose and glucose
Description: 500 ml water drink containing 40g fructose and 40g glucose
Study NCT01469676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtering group LG-6, Pall Biomedical Products
Description: In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
Study NCT03569644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: qualitative study
Description: Interviews
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally at the protocol-defined dose twice daily.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for epacadostat administered orally twice daily.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
Study NCT03348904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
Study NCT01241734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days
Study NCT00097591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally
Study NCT00097591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Administered orally
Study NCT02922036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE System
Description: The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
Study NCT01702792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Vaccine
Description: Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
Study NCT01271881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTA alone without use of the GORE VIABAHN
Description: PTA alone with no stent used
Study NCT02791581 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months.
Study NCT03713294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO
Study NCT03713294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV
Study NCT03713294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT03131466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency
Description: The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
Study NCT03131466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
Study NCT02099929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee with Sugar
Description: 300mL of Coffee with 30g of Sugar
Study NCT02099929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee without Sugar
Description: 300mL of Coffee without Sugar
Study NCT02099929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated Coffee without Sugar
Description: 300mL of Decaffeinated Coffee without Sugar
Study NCT02099929 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water with Sugar
Description: 300mL of Water with 30g of Sugar
Study NCT02099929 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water without Sugar
Description: 300mL of Water without Sugar
Study NCT01612780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XprESS Multi-Sinus Dilation Tool
Description: Sinus balloon dilation
Study NCT03291847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetal monitoring
Description: Maternal fetal monitoring
Study NCT03291847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Naloxone
Description: Treatment for opioid use disorder
Study NCT04011904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-over study
Description: Traditional Inuit Diet vs Westernized Diet
Study NCT04011904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cross-over study
Description: Traditional Inuit Diet vs Westernized Diet
Study NCT01271881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Description: Covered stent produced by GORE VIABAHN
Study NCT03963518 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Immune checkpoint inhibitor
Study NCT03333005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 with Standard of Care anti-fungal agent
Description: safety assessment
Study NCT03236337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI intervention
Description: MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
Study NCT00927017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquorice 66 g/day
Description: Liquorice 66 g/day for two weeks
Study NCT00927017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquorice 102 g/day
Description: Liquorice 102 g/day for two weeks
Study NCT02203019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
Study NCT02203019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
Study NCT02203019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest.
Study NCT01103297 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Variable Angle Distal Radius Plate ® (Surgery)
Description: Fracture reduction with distal radius plate
Study NCT04592705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP.
Study NCT02165722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Pillars Toolkit
Description: Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback).
Study NCT04298944 — intervention group
Intervention type: BEHAVIORAL
Intervention: Emotional/ Behavioural assessments
Description: Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
Study NCT02880852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
Study NCT03058796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contralaterally Controlled Functional Electrical Stimulation (CCFES)
Description: The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
Study NCT03058796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralaterally Controlled Functional Electrical Stimulation (CCFES)
Description: The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
Study NCT03058796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Therapy Video Games
Description: The use of video games with CCFES to encourage therapeutic hand movement at home
Study NCT02841423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuropsychological test battery
Study NCT04177524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Background Mode
Description: The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
Study NCT04177524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Mode
Description: In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button.
Study NCT04177524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Detect Mode
Description: In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle.
Study NCT00510029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GAP-134
Description: atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
Study NCT02974361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT02974361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Lysine
Study NCT02974361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH
Study NCT02406144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Study NCT02406144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Study NCT02406144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02406144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT03167437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
Study NCT03167437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
Study NCT02406144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01794949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Integrity stent
Description: Drug eluting stents used to treat coronary artery blockages
Study NCT01583725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal responses
Description: Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
Study NCT01583725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI responses to food-cues
Description: Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
Study NCT03509688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir+resveratrol
Description: entecavir+resveratrol
Study NCT03509688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir
Study NCT03509688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir+thymosin α1
Description: entecavir+thymosin α1